Prabotulinumtoxin A biosimilar by AEON Biopharma for Spasmodic Torticollis (Cervical Dystonia): Likelihood of Approval

Prabotulinumtoxin A biosimilar is under clinical development by AEON Biopharma and currently in Phase II for Spasmodic Torticollis (Cervical Dystonia).

Q&A: Gilead public affairs chief on new strategy, TikTok, and why the company won’t ‘keep doing things the same way’

After years of quiet focus on HIV and virology and stoic responses to flare-ups of attention over its pricing decisions, the new Gilead Sciences is

September 20, 2023

FDA adcomm votes in favor of Ipsen’s fibrodysplasia drug

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted in support of the efficacy and risk-benefit profile of Ipsen Biopharmaceuticals’ drug palovarotene, which the agency

June 29, 2023

Polio transmission was supposed to end by 2023. A new report explains why it won’t.

The latest goal for the end of polio transmission will almost certainly not be met, according to a frank and concerning report about the future

September 15, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.